Ellagic Acid and Resveratrol Prevent the Development of Cisplatin Resistance in the Epithelial Ovarian Cancer Cell Line A2780

Overview

Journal J Cancer

Specialty Oncology

Date 2016 Feb 27

PMID 26918049

Citations 36

Authors

Laura H Engelke

Alexandra Hamacher

Peter Proksch

Matthias U Kassack

Affiliations

Soon will be listed here.

Abstract

Purpose. Several studies have shown that natural compounds like resveratrol or ellagic acid have anticancer and antioxidant properties and can stimulate apoptosis in many cancer cell lines. The aim of this study was to elucidate if resveratrol or ellagic acid, respectively, could improve the efficacy of cisplatin in ovarian cancer. Methods. As a cellular resistance model, the epithelial ovarian cancer cell line A2780 and its cisplatin-resistant subclone A2780CisR were used. A2780CisR was obtained by intermittent treatment of A2780 with cisplatin for 26 weekly cycles and showed a 4-6-fold increased resistance towards cisplatin compared to A2780. Results. Pretreatment with resveratrol or ellagic acid 48 h prior to treatment with cisplatin showed a moderate enhancement of cisplatin cytotoxicity in A2780CisR cells (shift factors were 1.6 for ellagic acid and 2.5 for resveratrol). However, intermittent treatment of A2780 with cisplatin for 26 weekly cycles in permanent presence of resveratrol or ellagic acid, respectively, completely prevented the development of cisplatin resistance. The generated cell lines named A2780Resv and A2780Ellag displayed functional characteristics (migration, proliferation, apoptosis, activation of ErbB3, ROS generation) similar to the parental cell line A2780. Conclusion. In conclusion, weekly intermittent treatment cycles of cisplatin-sensitive ovarian cancer cells with cisplatin retain cisplatin chemosensitivity in permanent presence of ellagic acid or resveratrol, respectively, whereas clinically relevant cisplatin chemoresistance develops in the absence of ellagic acid or resveratrol. Use of natural phenolic compounds may thus be a promising approach to prevent cisplatin resistance in ovarian cancer.

Citing Articles

Exploring Alternative Zinc-Binding Groups in Histone Deacetylase (HDAC) Inhibitors Uncovers as a Potent Ethylhydrazide-Based HDAC Inhibitor with Chemosensitizing Properties.

Stopper D, Biermann L, Watson P, Li J, Konig B, Gaynes M J Med Chem. 2025; 68(4):4426-4452.

PMID: 39946728 PMC: 11867874. DOI: 10.1021/acs.jmedchem.4c02373.

A nanoscale natural drug delivery system for targeted drug delivery against ovarian cancer: action mechanism, application enlightenment and future potential.

Li Y, Shen Q, Feng L, Zhang C, Jiang X, Liu F Front Immunol. 2024; 15:1427573.

PMID: 39464892 PMC: 11502327. DOI: 10.3389/fimmu.2024.1427573.

Triple Combination of Entinostat, a Bromodomain Inhibitor, and Cisplatin Is a Promising Treatment Option for Bladder Cancer.

Bollmann L, Lange F, Hamacher A, Biermann L, Schaker-Hubner L, Hansen F Cancers (Basel). 2024; 16(19).

PMID: 39409994 PMC: 11476342. DOI: 10.3390/cancers16193374.

Tolypothrix Dichloromethane Ethylacetate fraction (TDEF) inhibits cisplatin resistance H357 cell through PI3K/AKT/beta-catenin pathway.

Heisnam R, Devi S, Mohanty S, Mukherjee P, Rayala V, Radhakrishnanand P Am J Cancer Res. 2024; 14(3):1071-1086.

PMID: 38590426 PMC: 10998759. DOI: 10.62347/JTNQ4812.

Ellagic Acid Prevents α-Synuclein Spread and Mitigates Toxicity by Enhancing Autophagic Flux in an Animal Model of Parkinson's Disease.

Radwan N, Khan E, Ardah M, Kitada T, Haque M Nutrients. 2024; 16(1).

PMID: 38201915 PMC: 10780534. DOI: 10.3390/nu16010085.

References

Nunez-Sanchez M, Gonzalez-Sarrias A, Romo-Vaquero M, Garcia-Villalba R, Selma M, Tomas-Barberan F . Dietary phenolics against colorectal cancer--From promising preclinical results to poor translation into clinical trials: Pitfalls and future needs. Mol Nutr Food Res. 2015; 59(7):1274-91. DOI: 10.1002/mnfr.201400866. View

Mueller H, Kassack M, Wiese M . Comparison of the usefulness of the MTT, ATP, and calcein assays to predict the potency of cytotoxic agents in various human cancer cell lines. J Biomol Screen. 2004; 9(6):506-15. DOI: 10.1177/1087057104265386. View

Johnson W, Morrissey R, Usborne A, Kapetanovic I, Crowell J, Muzzio M . Subchronic oral toxicity and cardiovascular safety pharmacology studies of resveratrol, a naturally occurring polyphenol with cancer preventive activity. Food Chem Toxicol. 2011; 49(12):3319-27. PMC: 3223276. DOI: 10.1016/j.fct.2011.08.023. View

Perchellet J, Gali H, Perchellet E, Klish D, Armbrust A . Antitumor-promoting activities of tannic acid, ellagic acid, and several gallic acid derivatives in mouse skin. Basic Life Sci. 1992; 59:783-801. DOI: 10.1007/978-1-4615-3476-1_47. View

Losso J, Bansode R, Trappey 2nd A, Bawadi H, Truax R . In vitro anti-proliferative activities of ellagic acid. J Nutr Biochem. 2004; 15(11):672-8. DOI: 10.1016/j.jnutbio.2004.06.004. View

Nessa M, Beale P, Chan C, Yu J, Huq F . Combinations of resveratrol, cisplatin and oxaliplatin applied to human ovarian cancer cells. Anticancer Res. 2012; 32(1):53-9. View

Coward J, Middleton K, Murphy F . New perspectives on targeted therapy in ovarian cancer. Int J Womens Health. 2015; 7:189-203. PMC: 4324539. DOI: 10.2147/IJWH.S52379. View

Darzynkiewicz Z, Juan G . Overview of nucleic acid analysis. Curr Protoc Cytom. 2008; Chapter 7:Unit 7.1. DOI: 10.1002/0471142956.cy0701s00. View

Chung Y, Lu L, Tsai M, Chen Y, Chen Y, Yao S . The inhibitory effect of ellagic Acid on cell growth of ovarian carcinoma cells. Evid Based Complement Alternat Med. 2013; 2013:306705. PMC: 3697306. DOI: 10.1155/2013/306705. View

10.

Ferry-Dumazet H, Garnier O, Mamani-Matsuda M, Vercauteren J, Belloc F, Billiard C . Resveratrol inhibits the growth and induces the apoptosis of both normal and leukemic hematopoietic cells. Carcinogenesis. 2002; 23(8):1327-33. DOI: 10.1093/carcin/23.8.1327. View

11.

Kundu J, Surh Y . Cancer chemopreventive and therapeutic potential of resveratrol: mechanistic perspectives. Cancer Lett. 2008; 269(2):243-61. DOI: 10.1016/j.canlet.2008.03.057. View

12.

Singh C, George J, Ahmad N . Resveratrol-based combinatorial strategies for cancer management. Ann N Y Acad Sci. 2013; 1290:113-21. PMC: 3713511. DOI: 10.1111/nyas.12160. View

13.

Stakleff K, Sloan T, Blanco D, Marcanthony S, Booth T, Bishayee A . Resveratrol exerts differential effects in vitro and in vivo against ovarian cancer cells. Asian Pac J Cancer Prev. 2012; 13(4):1333-40. DOI: 10.7314/apjcp.2012.13.4.1333. View

14.

Block K, Koch A, Mead M, Tothy P, Newman R, Gyllenhaal C . Impact of antioxidant supplementation on chemotherapeutic toxicity: a systematic review of the evidence from randomized controlled trials. Int J Cancer. 2008; 123(6):1227-39. DOI: 10.1002/ijc.23754. View

15.

Liang Y, Tsai S, Chen L, Lin-Shiau S, Lin J . Resveratrol-induced G2 arrest through the inhibition of CDK7 and p34CDC2 kinases in colon carcinoma HT29 cells. Biochem Pharmacol. 2003; 65(7):1053-60. DOI: 10.1016/s0006-2952(03)00011-x. View

16.

Stoner G, Morse M . Isothiocyanates and plant polyphenols as inhibitors of lung and esophageal cancer. Cancer Lett. 1997; 114(1-2):113-9. DOI: 10.1016/s0304-3835(97)04639-9. View

17.

Jurenka J . Therapeutic applications of pomegranate (Punica granatum L.): a review. Altern Med Rev. 2008; 13(2):128-44. View

18.

Sithanandam G, Fornwald L, Fields J, Anderson L . Inactivation of ErbB3 by siRNA promotes apoptosis and attenuates growth and invasiveness of human lung adenocarcinoma cell line A549. Oncogene. 2005; 24(11):1847-59. DOI: 10.1038/sj.onc.1208381. View

19.

Mertens-Talcott S, Percival S . Ellagic acid and quercetin interact synergistically with resveratrol in the induction of apoptosis and cause transient cell cycle arrest in human leukemia cells. Cancer Lett. 2005; 218(2):141-51. DOI: 10.1016/j.canlet.2004.06.007. View

20.

Narayanan B, Re G . IGF-II down regulation associated cell cycle arrest in colon cancer cells exposed to phenolic antioxidant ellagic acid. Anticancer Res. 2001; 21(1A):359-64. View